arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Sana Biotechnology, Inc.

SANA

$3.52 ▲ +0.10 (+3.08%) at close

8 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Sana Biotechnology, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $891.4M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -122.9% ↘

FCF / Share $-0.57 ↗

Trailing P/E —

Price / Book 5.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-244.17M

↑ +8.5% —

FCF / Share Free cash flow per share

$-0.57

↑ +48.6% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
EPS Growth YoY (%)	17.2% Good → Good Stable Year-over-year change in earnings per share Optimal: > 10%	20.5% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	-2.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	33.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	8.5% Fair → Fair Stable Year-over-year change in net income	5.8% Fair ↑ Fair Improving Year-over-year change in net income	-5.1% Weak ↑ Weak Improving Year-over-year change in net income	24.3% Good ↑ Good Improving Year-over-year change in net income	-24.8% Weak Weak Year-over-year change in net income	-118.2% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	48.6% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	21.0% Good ↑ Good Improving Year-over-year change in free cash flow	14.8% Fair Fair Year-over-year change in free cash flow	2.2% Caution Caution Year-over-year change in free cash flow	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Effective Tax Rate (%) (%)	—	—	—	—	—	—	5.5% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	0.59x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.15x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.57x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-122.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-86.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-80.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-43.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-38.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	53.7% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	93.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-60.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-54.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-51.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-33.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-31.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-39.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-151.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1112%)	-106.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-810%)	-98.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-757%)	-54.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-460%)	-48.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-426%)	67.7% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+352%)	91.7% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+512%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Net Debt (USD)	$-71.87M	$-127.57M	$-133.52M	$-176.76M	$-253.03M	$-124.81M	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Basic EPS, GAAP (USD)	$-0.96	$-1.16	$-1.46	$-1.43	$-2.14	—	—	—
Free Cash Flow per Share (USD)	$-0.57	$-1.11	$-1.41	$-1.65	$-1.69	—	—	—
Book Value per Share (USD)	$0.60	$1.12	$1.45	$2.61	$3.94	$-26.05	—	—
Tangible Book Value per Share (USD)	$-0.15	$0.23	$0.44	$1.57	$2.86	$-38.40	—	—
Basic Weighted Avg Shares (shares)	253.23M	230.89M	194.54M	188.34M	166.43M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$69.95M	$115.38M	$149.03M	$332.93M	$458.87M	$353.02M	—	—
Total Equity (USD)	$160.88M	$250.50M	$287.51M	$499.31M	$728.50M	$-421.18M	$-142.54M	$-13.19M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Depreciation Expense (USD)	$12.80M	$15.50M	$24.60M	$15.60M	$11.07M	$5.92M	$1.83M	—
Net Income, GAAP (USD)	$-244.17M	$-266.76M	$-283.25M	$-269.48M	$-355.93M	$-285.31M	$-130.78M	—
Operating Cash Flow (USD)	$-143.83M	$-223.15M	$-253.58M	$-290.05M	$-251.05M	$-137.98M	$-85.52M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 27 quarters

Sana Biotechnology, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare SANA with peers